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Hepatitis C virus infection is a major cause of chronic liver disease. CD4+ T cells play a
key role in disease outcome. However, the critical functions and associated phenotypes
of intrahepatic CD4+ T cells are not well defined. We have previously shown that CD8+ T
cells expressing the C type lectin CD161 are highly enriched in the human liver, especially
during chronic hepatitis. These cells are associated with a type 17 differentiation pattern
and express cytokines including IL-17A, IL-22, and IFN-γ.We therefore analyzed expression
of CD161 on CD4+ T cells in blood and liver and addressed the relevant phenotype and
functional capacity of these populations.Weobservedmarked enrichment of CD161+CD4+
T cells in the liver during chronic hepatitis such that they are the dominant subtype (mean
55% of CD4+ T cells). IL-22 and IL-17 secreting CD4+ T cells were readily found in the
livers of HCV+ and NASH donors, although not enriched compared to blood. There was,
however, specific enrichment of a novel subset of IL-22/IFN-γ dual secretors (p = 0.02)
compared to blood, a result reconfirmed with direct ex vivo analyses. These data indicate
the dominance of CD161+ expressing lymphocyte populations within the hepatic infiltrate,
associated with a distinct cytokine profile. Given their documented roles as antiviral and
hepatoprotective cytokines respectively, the impact of co-secretion of IFN-γ and IL-22 in
the liver may be particularly significant.
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INTRODUCTION
Hepatitis C virus (HCV) infects 170million people worldwide and
is a major cause of liver disease (Lauer andWalker, 2001). The role
of T cells in control of infection has been extensively studied and
it is clear that both CD4+ and CD8+ T cells contribute impor-
tantly to disease outcome. There is evidence from animal models,
immunogenetics and correlative studies that both sets of T cells
are involved in control of viremia after acute infection (Cooper
et al., 1999; Lechner et al., 2000; Thimme et al., 2002; McKiernan
et al., 2004; Bowen and Walker, 2005). However, in the majority
of those infected, the virus is able to evade innate and adaptive
immune responses and to establish persistence. In these individu-
als, T cell infiltrates are still maintained within liver tissue (Koziel
et al., 1992; Wong et al., 1998). However, their subsequent com-
position and overall roles in control of virus, immune-mediated
pathology, and tissue remodeling are not well defined.
In terms of CD4+ T helper cell responses, much attention has
focused on Th1 cells, since secretion of interferon-gamma (IFN-
γ) has been proposed to be linked to control of hepatotropic
viruses (Guidotti et al., 1999). Some studies indicated the pres-
ence of Th2 responses in chronic infection, which may play a
role in outcome (Prezzi et al., 2001; Nelson et al., 2003). Recently
some attention has turned to Treg responses, characterized by
expression of the transcription factor FOXP3. These are enriched
within the liver (Ward et al., 2007) and may play a modifying
role by down-regulating immunopathogenic as well as antiviral
responses. A furtherT cell subset has beenmore recently described,
named Th17, or type 17 T cells, associated with IL-17A produc-
tion (McGeachy and Cua, 2008; Tesmer et al., 2008). IL-17A is a
pleiotropic cytokine which has been linked to induction of tissue
inflammation and recruitment of inflammatory cells in models of
inflammatory bowel disease and encephalomyelitis.
Type 17 cells also produce other cytokines, including, impor-
tantly, IL-22. This molecule, which is of the IL-10 family, has
been shown to be hepatoprotective in murine models of hepati-
tis (Wolk and Sabat, 2006; Zenewicz et al., 2007). In such models,
depletion of IL-17 had little impact on the course of inflammation,
but blockade or knockout of IL-22 had a major deleterious effect.
It is thought the cytokine acts through promoting anti-apoptotic
pathways or pro-proliferative pathways in IL-22R+ hepatocytes
(Fickenscher et al., 2002; Pan et al., 2004; Dambacher et al., 2008).
A similar activity in skin may promote the pathogenesis of psori-
asis through dysregulated keratinocyte proliferation (Fickenscher
et al., 2002). In other tissues it has been shown that in addition to
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this, IL-22 promotes epithelial defense responses through secre-
tion of antimicrobialmolecules (Wolk et al., 2004;Wolk and Sabat,
2006; Aujla et al., 2008; Eyerich et al., 2009). Thus, this is a unique
and important cytokine with potent effects on tissue repair and
remodeling, which has a specific role in the liver in modulating
tissue injury.
In man, many Th17 cells can co-secrete IFN-γ, as well as IL-22
(Annunziato et al., 2008; Cosmi et al., 2008). Additionally, recently
a subset of cells which secretes IL-22 but not IL-17 or IFN-γ,
termed Th22, have been described; however, these have been con-
sidered up until now specific for the skin and whether they may
play any role in the liver is unknown (Duhen et al., 2009; Eyerich
et al., 2009). Overall the role of Type 17 CD4+ T cells in the liver
during chronic hepatitis C has not been extensively evaluated. A
recent study by the group of Rosen, looking at end-stage liver dis-
ease, did reveal enrichment of CD4+ T cells secreting IL-17 in
comparison to blood in 11 patients (Foster et al., 2012), although
the nature of the infiltrate at earlier stages of infection remains
to be determined, and the co-expression of IL-17 or IL-22 with
IFN-γ has yet to be defined.
CD161 is a C type lectin – initially defined as an NK associated
molecule –which has been linked to a liver homing phenotype of T
cells in health and disease (Northfield et al., 2008; Billerbeck et al.,
2010). CD161 is expressed on both CD3+CD8+ and CD3+CD4+
T cells (Takahashi et al., 2006) and recently CD161 expression has
been linked to both a “TH17” and a “TC17” phenotype in man
(Cosmi et al., 2008; Billerbeck et al., 2010). CD8+ T cells express-
ing high levels of CD161 are highly enriched in the livers of patients
with chronic hepatitis, expressing chemokine receptors associated
with tissue homing in resting and inflammatory conditions (Biller-
beck et al., 2010). These cells have a distinct phenotype and may
secrete IL-17, IL-22, TNFα, and/or IFN-γ. Data from the study of
cord blood T cells suggest that CD161 expression occurs very early
and that only cells that express this molecule, and therefore the
master transcription factor RORγt, are able to differentiate further
into IL-22 and IL-17 secreting cell populations (Annunziato et al.,
2008; Cosmi et al., 2008; Romagnani et al., 2009; Billerbeck et al.,
2010; Maggi et al., 2010). Thus, CD161+ CD4+ T cells possess
enhanced potential to secrete IL-22 compared to CD161 T cells.
Given our prior data onCD8+ CD161+ T cells discussed above,
we therefore characterized in a parallel way the phenotype and
function of CD4+ T cells in blood of chronically HCV+ donors
and controls, and analyzed the function of the infiltrate in the
liver. Our data suggest that CD4+ T cells expressing CD161 are
an important component of the inflammatory infiltrate in HCV
and other inflammatory liver diseases. This includes a distinct IL-
22/IFN-γ+ population which is specifically enriched in the liver
and may be of particular functional significance.
MATERIALS AND METHODS
PATIENTS AND HEALTHY DONORS
Hepatitis C virus infected patients, patients with non-viral hep-
atitis, and healthy normal donors were enrolled in this study
after informed consent: the patient characteristics of the liver
biopsy study cohorts are tabulated in Table 1. All those studied –
both HCV+ and non-alcoholic steatohepatitis (NASH) cohorts –
were undergoing liver biopsies for diagnostic reasons related to
Table 1 | Subject characteristics for in vitro analysis.
Subject Age Gender Viral load (U/ml) Fibrosis
(Metavir)
Chronic HCV
18 48 F 1480000 2
19 52 M 1438180 2
20 54 M 1500000 2
21 63 F 2568188 2
22 56 F 938114 2
23 43 M 915735 3
24 28 M 999416 1
25 62 M 1
26 57 M 123277 3
27 50 M 737087 3
28 44 F 572472 1
29 50 M 4011231 2
30 66 F 639838 3
31 72 F 2904622 3
32 49 M 15800000 3
33 65 F 208729 1
34 32 M 112622 1
35 43 M 864679 1
36 33 F 184445 2
NASH
1 29 M n.a.
2 53 M n.a.
3 32 F n.a.
4 56 F n.a.
5 55 M n.a.
6 40 M n.a.
7 54 M n.a.
8 51 F n.a.
9 39 M n.a.
10 53 M n.a.
11 32 M n.a.
their normal clinical care as in previous analyses (Billerbeck et al.,
2010). For healthy donor studies, peripheral blood mononuclear
cells (PBMCs) from groups of up to 12 HCV-negative, low risk
healthy controlswere analyzed. A further set of HCV+ patients and
intrahepatic lymphocytes (IHL) from explants from five donors
undergoing liver transplant were used for the comparative study
in Figure 3 and this information is briefly summarized in the rele-
vant legend. The study protocol conforms to the ethical guidelines
of the 1975Declaration of Helsinki as reflected in a priori approval
by the institutions’ human research committees.
CELL PREPARATION
Peripheral blood mononuclear cells, liver cells, and liver-derived
cell lines were prepared as previously (Spangenberg et al., 2005).
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Briefly, for the isolation of intrahepatic lymphocytes (IHL) the
liver tissue was washed twice in 3 ml of phosphate buffered saline
(PBS) containing 1% FCS prior to a careful homogenization
through a 70 μm cell strainer (BD Falcon). The homogenized
cell suspension was incubated with magnetic microbeads cov-
ered with anti-CD4 (Dynal, Oslo, Norway) for 30 min at 4ºC.
CD4+ T cells bound to the microbeads were isolated from the
cell suspension by using a magnetic bead concentrator (Dynal).
Peripheral CD4+ T cells were isolated from 4 × 106 PBMC by the
same experimental approach. The purity of each T cell subset was
confirmed by FACS analysis and was always>95%. Isolated intra-
hepatic and peripheral CD4+ T cells were resuspended in 1 ml of
complete medium and cultured in a 48-well plate (Greiner, Frick-
enhausen, Germany) in the presence of 100 U/ml human rIL-2
(HoffmannLaRoche, Basel, Switzerland), 0.04μg/ml human anti-
CD3 antibody (Immunotech, Marseilles, France), and 2 × 106
irradiated autologous PBMC as feeder cells. Twice a week the
medium was exchanged and 100 U/ml IL-2 was added. After
2 weeks of expansion, cells were analyzed for cytokine produc-
tion as described below. For ex vivo analyses the same approach
to isolate the cells was taken to obtain the cells from blood
and liver but no in vitro selection and expansion steps were
used. The cells were stimulated and analyzed in short-term assays
as below.
LYMPHOCYTE STAINING AND ANALYSIS
Lymphocyte staining was performed on whole blood as previ-
ously (Northfield et al., 2008), using antibodies as indicated below.
Intracellular cytokine staining after PMA/Ionomycin stimulation
was performed as previously (Northfield et al., 2008; Bengsch et al.,
2012). Cellswere analyzedon aBDLSRIImachine, BDFACSCanto
or BD FACSCalibur machine using FlowJo software. Samples
were gated on live, singlet CD3+ lymphocytes. Non-parametric
tests, Mann–Whitney and Wilcoxon were used throughout for
unpaired/paired comparisons respectively (Prism software v5).
ANTIBODIES
Anti-CD8-PerCP, anti-CD8-PE, anti-CD8-PerCP-Cy5.5, anti-
CD8-Alexafuor700-anti-CD4-PerCP, anti-CD4-FITC, anti-CD4-
APC, anti-IFN-γ-FITC, anti-TCRγδ-PE, anti-TCRαβ-PE, anti-
TNF-α, isotype PE, isotype FITC, and isotype APC were
obtained fromBDPharmingen (Heidelberg,Germany). Anti-CD3
FITC/APC, anti-IL-22-APC, anti-CCR6-APC, anti-CCR2-APC,
anti-CXCR6-PE, anti-CXCR3-FITC, anti-CCR7-FITC, biotin-
anti-IL23R, and anti-IFN-γ-FITC were obtained from R&D
Systems (Minneapolis, MN, USA), anti-CD161-APC from Mil-
tenyi Biotech (Bergisch-Gladbach, Germany). Anti-IL17A-PE,
anti-IL17A-Alexa647, anti-TCRαβ-APC, anti-CD127-PE, anti-
RORγT-PE, and anti-IL18R-FITC were from eBioscience (San
Diego, CA, USA). Anti-CD161-PE and anti-CD3-ECD obtained
from Immunotech/Beckman Coulter (Fullerton, CA, USA).
Anti-CD3-Pacific Orange was obtained from Caltag Laborato-
ries (Buckingham, UK). Anti-RORγT-Alexa 488 was obtained
from Cambridge Biosciences (Cambridge, UK). FITC- or APC-
conjugated antibodies to CD45RA, CD45RO, CD38, CD62L,
CD56, CD103, TGFβRII, PD-1, ICOS, GITR, CD38, CD62L,
CCR5, CXCR4, CD85j, CD27, CD28 were obtained from BD
Pharmingen and R&D systems. Extravidin-PE was obtained from
Sigma (St. Louis, MO, USA).
RESULTS
FUNCTION AND PHENOTYPE OF CD161+CD4+ T CELLS IN HEALTHY
DONOR BLOOD
Initially, we examined the immediate effector functions of
CD161+ and CD161- CD4+ T cells in healthy donors. To do
this we stimulated populations taken directly ex vivo from healthy
donors with PMA/Ionomycin and examined cytokine production
by intracellular cytokine secretion. CD161+CD4+ T cells gener-
ated high levels of IL-17A upon stimulation, compared toCD161−
cells (mean = 7%; Figure 1A). We noted co-secretion of IL-17A
and IFN-γ, as previously described for CD8+ T cells (Billerbeck
et al., 2010; data not shown). Importantly, we readily identified ex
vivo secretion of hepatoprotective IL-22 by a larger fraction of cells,
and found this to be strongly associated with the CD161+CD4+
T cell subset (mean = 10%; Figure 1B).
To further characterize this subset of T cells for features
relevant to liver homing, we next analyzed expression of rele-
vant chemokine receptors in relation to CD161. We found co-
expression of CCR6 (45%), as well as CCR2 (30%; Figures 2A,D).
We noted high expression of CXCR3, a chemokine receptor linked
to homing to inflammatory sites (45%) although CD161+CD4+
T cells did not express CXCR6 – a key chemokine recep-
tor associated with immunosurveillance in the liver sinusoids
(Geissmann et al., 2005; Sato et al., 2005; Figures 2B,C). We
also confirmed that circulating CD4+CD161+ cells analyzed ex
vivo expressed the cytokine receptor IL-23R, high levels of the
IL-18Rα and increased levels of RORγt expression compared
to CD161− cells (data not shown) similar to data from CD8+
CD161+ cells (Billerbeck et al., 2010). In terms of other effec-
tor/memory markers, these CD4+ T cells displayed an “effector
memory” phenotype (CD45ROhi, CD45RAlo, CD62Llo, CCR7lo,
CD28hi, CD27hi, perforinlo, Granzyme Blo) without evidence of
exhaustion (PD-1lo; data not shown).
These data confirm and further define some important func-
tional capacities of the CD161+ T cell subset. The cells express
relevant chemokine receptors for liver homing during inflamma-
tion and relevant cytokine receptors and transcription factors for
IL17/IL-22 induction and maintenance. The CD161+CD4+ T cell
fraction also includes IL-22+ cells with the ability to express IFN-γ
and/or IL-17 as well as IL-22 mono-secreting cells.
CD161+CD4+ T CELLS ARE ENRICHED IN THE LIVER DURING CHRONIC
HEPATITIS C
Having established their baseline function and phenotype in
healthy donors, we next addressed whether CD161+CD4+ T cells
were associatedwith intrahepatic infiltrates during chronic hepati-
tis C infection.Wenoted amarked enrichment of CD161+CD4+ T
cells derived from liver tissue from HCV+ donors, with up to 50%
of infiltrating CD4+ T cells expressing this molecule (Figure 3A).
In blood, there was a significant decrease in the frequency of
CD4+ T cells expressing CD161 in HCV+ individuals compared
to healthy donors (p = 0.02; Figure 3A).
We next analyzed whether HCV had any impact on the phe-
notype of CD161+CD4+ T cells in blood, in addition to affecting
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FIGURE 1 | Cytokine secretion capacity of CD161+CD4+ T cells in healthy
donor blood. Healthy donor blood ex vivo was stained as described in
methods and analyzed for expression of the following cytokines following
PMA/Ionomycin stimulation: IL-17A (A), IL-22 (B) Plots show gated live
CD3+CD4+ lymphocytes. In each case an example is shown on the left and
group data on the right, with comparison by MannWhitney test.
their frequency.We found the relative reduction of CD161+CD4+
T cells in blood occurred most significantly amongst CXCR3+
CD161+CD4+ T cells (Figure 3B). The expression of the other
markers on CD4+ T cells analyzed, including CXCR6, was not
affected by HCV infection (Figure 3B and data not shown). This
feature is consistent with homing of CXCR3+ T cells to the liver as
has been indicated in previous studies (Boisvert et al., 2003; Wang
et al., 2004).
ANALYSIS OF CYTOKINE SECRETING CD4+ T CELLS IN THE LIVER IN
HCV INFECTION
We next examined the functional capacity of CD4+ T cells derived
from the liver biopsies of HCV+ persons, focusing on IL-22 and
IL-17 production. Initially, as previously in our studies of CD8+
T cells, we used populations of CD4+ T cells which had been
expanded in vitro using non-specific stimuli (Billerbeck et al.,
2010). Exactly parallel stimulations with PMA/Ionomycin were
thenperformedusing blood and liver-derived cells (Figures 4A,B).
We compared data between CD4+ and CD8+ T cell
subsets.
We confirmed that IL-22 and IL-17 secreting CD4+ T cells
were readily detectable within liver-infiltrating lymphocyte (LIL)
populations (Figures 4A,B). IL-22 secreting CD4+ T cells com-
prised on average 4.7% of the CD4+ T cell infiltrate, compared to
2.2% of the IL-17 secreting cells (p = 0.02). The levels of CD4+
T cells and CD8+ T cells secreting IL-17 in liver tissue were not
significantly different from each other, while in blood, CD4+ T
cells secreting IL-17 were significantly more numerous than their
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FIGURE 2 | Chemokine receptor expression of CD161+ CD4+ T cells in
healthy donor blood. Healthy donor blood was stained as described in
methods and analyzed for expression of the following chemokine receptors:
CCR6 (A), CXCR6 (B), CXCR3 (C), and CCR2 (D). Plots show gated live
CD3+CD4+ lymphocytes. In each case an example is shown on the left and
group data on the right, with comparison by Mann–Whitney test.
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FIGURE 3 | CD161+CD4+ T cells in blood and liver in HCV infection.
CD161+CD4+CD3+ T cell frequencies were examined in blood from healthy
donors, HCV+ chronically infected donors and liver derived lymphocytes,
studied ex vivo (A). Percentage CD161+ cells amongst CD4+ T cells in liver
explants, PBMC from HCV+ donors and PBMC from healthy donors are
shown. The 15 HCV+ donors studied in the analysis of PBMC were additional
to those inTable 1 and comprised persistently infected donors (eight genotype
1, six genotype 3, one genotype 2), of whom five had Ishak histologic scores
of 5+/6 and/or clinical cirrhosis; the IHL in this study were obtained at explant
for cirrhosis from HCV+ donors. Groups were compared by Mann-Whitney
tests. In (B), the phenotype of CD161+CD4+CD3+ T cells in peripheral blood
of HCV+ donors and healthy controls were compared as in Figures 1 and 2.
Data is shown from CXCR3 and CXCR6 analyses. No significant change was
seen in analyses of CD27, CD28, CD45RA/RO, CD62L, CCR6, CD103, or PD-1.
CD8+ counterparts (Figure 4A). For CD8+ T cells there was a
marked enrichment of IL-17 secreting cells in liver compared to
blood, but forCD4+ T cells the levels were very similar in both sites
and the differenceswere not significant (Figure 4A). IL-22+ CD4+
populations were also not enriched in liver compared to blood but
were significantly more numerous than their CD8+ counterparts
in both locations (Figure 4B). Both IL-22+ and IL-17+ CD4+ T
cells were markedly outnumbered by IFN-γ secreting cells (40%;
both p < 0.001; Figure 4C).
To assess whether these results were restricted to HCV, we also
compared a set of patients with NASH using identical protocols.
Overall, remarkably similar results were obtained (Figure 4C);
the frequencies and relative distributions of CD4+ T cells secret-
ing IL-17, IL-22, and IFN-γ were very similar to those obtained
in HCV+ patients, with both IL-17+ and IL-22+ populations
present, but outnumbered clearly by IFN-γ+ CD4+ T cells
(p < 0.001).
CO-SECRETION OF IL-22 WITH OTHER CYTOKINES BY CD4+ T CELLS IN
THE HUMAN LIVER
Since we had identified IL-22- secreting CD4+ T cells within the
liver infiltrates, we next addressed whether these cells co-secreted
other cytokines. Previous reports have describedT cells that secrete
IL-22 but not IFN-γ or IL-17 (Duhen et al., 2009; Eyerich et al.,
2009) in skin (Th22 cells) and we asked whether such cells exist
within the liver-homing populations.
We identified clear subsets of CD4+ T cells that have a “Th22”
phenotype (Figure 5A), i.e., these cells secrete IL-22, but not IFN-
γ or IL-17A. However, the frequencies of IL-22 monosecretors
as a fraction of IL-22 secreting cells were similar in blood and
liver overall (Figure 5B). Interestingly, we also noted a consistent
and significant enrichment of IL-22/IFN-γ dual secreting cells
within the liver compartment (p = 0.0018; Figure 5B). In the
tissue-derived cells these populations represented more than 50%
of the IL-22 population on average. Indeed, taking into account
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FIGURE 4 | Analysis of cytokine secreting cells in the liver of HCV+
persons and controls. (A) Liver-derived and blood-derived CD4+
and CD8+ lymphocytes were analyzed for their cytokine secretion
capacity as described in methods. The fractions of cells secreting IL-17A
are indicated. (B) Data for IL-22 secretion in blood and liver are indicated
as for IL-17A. (C) Analysis of CD4+ T cell cytokine secretion (IFN-γ vs
IL-22 and Il-17) in liver, in patients with HCV (left panel) and NASH
(right panel).
those cells that additionally secreted IL-17 (i.e., triple producers;
Figure 5B), this was clearly the dominant population in the liver.
ANALYSIS OF EX VIVO SECRETION OF IL-22 IN BLOOD AND LIVER
DERIVED CD4+ T CELL POPULATIONS
To address further the significance of these results a further
set of analyses were performed ex vivo on liver-derived and
blood-derived cells from a further 10 patients. Ex vivo derived
cell populations were those isolated fresh from blood or tissue
and then subjected to PMA/Ionomycin stimulation and intracel-
lular cytokine staining without any further expansion in vitro.
Using these freshly obtained cell populations we observed com-
parable patterns of response to those obtained with cultured
cells. Firstly, we observed readily detectable levels of IL-22+ cells
www.frontiersin.org November 2012 | Volume 3 | Article 346 | 7
“fimmu-03-00346” — 2012/11/17 — 20:01 — page 8 — #8
Kang et al. Intrahepatic IL-22 secreting T cells
FIGURE 5 | Analysis of IL-22 secreting cells and polyfunctionality in blood
and liver derived lymphocytes. Liver derived lymphocytes and PBMCs from
HCV+ donors expanded in vitro were analyzed in parallel for expression of
cytokines IL-17A, IL-22 and IFN-γ in response to PMA/Ionomycin stimulation
as described in methods. In (A) an example of staining is shown. IL-22+
CD4+ T cells were gated upon and co-secretion of IL-17A and IFN-γ was
assessed. In (B) the fraction of cells secreting IL-22 either alone or in
combination with the other cytokines is displayed and compared (paired
Student’s t -test). A significant enrichment of liver-derived IFN-γ/IL-22
co-secreting cells is observed.
ex vivo (Figure 6A). We next analyzed the polyfunctionality of
IL-22+ cells regarding co-secretion of IFN-γ and IL-17A. Impor-
tantly, once again we found specific enrichment of IL-22/IFN-γ
dual secreting cells and also of IL-22/IFN-γ/IL-17A triple secret-
ing cells in the liver, confirming the significance of this finding
(Figure 6B).
DISCUSSION
These data provide a novel insight into the composition of the
inflammatory infiltrate in chronic liver disease. Despite the clear
evidence from animal models, we do not yet know to what extent
IL-22 secreting T cells participate in different stages of human liver
disease, their impact in tissue, or to what extent measurement of
such cells in blood or liver may vary or correlate with clinical
outcome. These data represent an important step in the direction
of defining the significance of this relevant cytokine in chronic
hepatitis.
Although we have focused on HCV, since this is a major clinical
problem, a comparable profile was observed in non-viral inflam-
mation. Indeed, since previous data have shown that there is
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FIGURE 6 | Analysis of IL-22 secretion and polyfunctionality in blood and
liver derived lymphocytes studied directly ex vivo. Liver derived
lymphocytes and PBMCs were analyzed in parallel directly following isolation
for expression of cytokines IL-17A, IL-22 and IFN-γ in response to
PMA/Ionomycin stimulation. In (A) an example of staining is shown. IL-22+
CD4+ T cells were gated upon and co-secretion of IL-17A and IFN-γ was
assessed. In (B) the fraction of cells secreting IL-22 either alone or in
combination with the other cytokines is displayed and compared using paired
Student’s t test in blood and liver. A significant enrichment of intrahepatic
IL-22/IFN-γ co-secreting cells and IL-22/IFN-γ/IL-17A triple secretors is observed.
relative enrichment of CD161+ T cells in the livers of normal
healthy donors (Norris et al., 1999), we postulate this may rep-
resent a interesting functional potential of liver homing cells. It
should be stressed that the absolute numbers of LILs are relatively
low in normal livers, and markedly increased in the setting of
chronic liver inflammation. Further work is required to define the
cytokine secretion of both the CD4+ and CD8+ CD161+ T cells
in the absence of an inflammatory milieu.
We focused on the phenotype and function of CD161+ CD4+
T cells in health and disease for two reasons. Firstly, CD161 has
been linked to LIL populations in humans, as in this paper and in
our previous work, which showed enrichment on antigen-specific
CD8+ T cells specific for hepatotropic viruses (Northfield et al.,
2008), as well as on bulk CD4+ T cell populations (Foster et al.,
2012). Secondly, it has been recently shown that Th17 popula-
tions express CD161, using an expression microarray approach
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(Cosmi et al., 2008). Our work is consistent with these findings.
CD161+CD4+ T cells found in blood express not only the classical
chemokine receptor associated with Th17 populations, CCR6, but
also a range of others, includingCCR2 andCXCR3. T cells express-
ing all three receptors have been found enriched within the liver
of HCV+ donors (Boisvert et al., 2003; Wang et al., 2004). Func-
tionally, a fraction secrete IL-17A in a short-term stimulation assay,
although interestingly a higher frequency in such assays express IL-
22, as well as a clear production of IFN-γ. This indicates that there
are many IL-22+/IL-17− populations, as well as IL-22+/IFN-γ+
populations, and this was confirmed by dual staining.
The role of the cytokines secretedwithin liver tissue is an impor-
tant area to be addressed. IL-17A to date has not been shown
to have a major influence on outcome in liver disease models
(Zenewicz et al., 2007). In contrast, however, there is a dominant
hepatoprotective role of IL-22 in vivo. Both blockade of IL-22 and
genetic knockout of IL-22 revealed a major effect of this cytokine
in the ConA hepatitis model (Zenewicz et al., 2007). IL-22 has a
major influence on hepatocyte biology through triggering via the
IL-22R. IL-22 may protect directly against hepatic damage since
it is known to promote proliferation and limit apoptosis (Wolk
et al., 2004; Zenewicz et al., 2007; Dambacher et al., 2008; Park
et al., 2010). We have further analyzed the impact of IL-22 on
gene expression patterns in human hepatocyte lines in vitro and
confirm these data, indicating that the major up-regulated gene
families relate to cell division (Ramamurthy et al., manuscript in
preparation). This is also consistent with the proven impact of IL-
22 overexpression in vivo in promoting tumor growth (Park et al.,
2010).
Recent studies have addressed whether type 17 cells may be
identified in the liver during chronic hepatitis B and C (Zhang
et al., 2011; Foster et al., 2012), although their overall role in dis-
ease progression is still not clear. Foster et al. (2012) addressed the
levels of CD4+ T cells expressing IL-17 and IL-22 in 11 patients
with end-stage liver disease. They noted enrichment of IL-17A, IL-
17F, and IL-22 secreting populations in liver compared to blood
when analyzed ex vivo, although the overall levels of production in
liver derived cells were similar to those in this study. An important
differencemay lie in the nature of the patients, who were undergo-
ing liver transplantation for cirrhosis, compared to the relatively
mild disease in our group. We were not able to reliably detect
IL-17F by flow cytometry in our studies despite using a range of
commercially available antibodies (data not shown).
We attempted to correlate the frequencies of cytokine secreting
cells with clinical parameters in our patient groups. Analysis of
correlation with disease stage, ALT, or viral load did not reveal any
significant relationship for CD4+ T cells expressing IL-17, IL-22,
or IFN-γ. Although we did not find an association between Th17
or Th22 levels in tissue and clinical state in our study, one caveat is
that most patients had relatively mild disease, and there were very
few with severe levels of fibrosis. The impact of these cells in long
term disease progression (of HCV infection and other inflamma-
tory diseases of the liver), therefore, requires future longitudinal
studies.
Interestingly, there do appear to be subsets of “Th22-like” cells
in the human liver. This subset has been described by the group
of Lanzavecchia; differentiation appears to be driven by IL-6 and
TNFα, and may also be triggered by plasmacytoid dendritic cells
(Duhen et al., 2009). These cells have been shown to express CCR6,
CCR4, and CCR10. CCR6 has been linked to mucosal surveillance
and Th17 differentiation (Schutyser et al., 2003; Acosta-Rodriguez
et al., 2007; Liu and Rohowsky-Kochan, 2008; Eyerich et al., 2009).
Thus, the features of the Th22 subset extend beyond the skin and
are likely to include other relevant epithelial tissues and certainly
the liver.
The most interesting finding of our study was the consis-
tent enrichment of IL-22/IFN-γ co-producing CD4+ T cells in
liver. Their in vivo function was not elucidated in this study, but
interestingly, IL-22R expression may be up-regulated by IFN-γ
(Wolk et al., 2004). This implies that the IFN-γ/IL-22 secreting
cell population may have a particularly relevant role in this tis-
sue, potentially augmenting the impact of IL-22. IFN-γ itself
clearly has important pro-inflammatory and antiviral properties
in HCV. Additionally there appear to be many other cytokines
and chemokines which may be co-secreted with IFN-γ or IL-22
by the CD161+ T cell population (Fleming et al., manuscript in
preparation) and, therefore, further description of the true func-
tional potential of the IL-22/IFN-γ-secreting CD4+ T cell subset
in health and disease is an important future goal.
In summary, we have analyzed the CD4+ T cell infiltrate in
the liver in chronic HCV, focusing on CD161 expression and
associated cytokine secretion. Within liver tissue we identified a
population of CD4+ T cells which are consistently enriched and
which co-secrete IL-22 and IFN-γ. Both these cytokines are of
likely significance in the pathogenesis of human liver disease. To
what extent these cells play a role in long-term evolution of dis-
ease and whether modulation of the appropriate pathways could
influence this process, are important questions for the future.
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